Teva Plans Copaxone sNDA For Earlier Use In MS Patients After First Clinical Event
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing is based on interim analysis of a trial showing glatiramer reduced risk of developing clinically definite multiple sclerosis.